JP5916752B2 - ５−クロロ−ｎ２−（２−イソプロポキシ−５−メチル−４−ピペリジン−４−イル−フェニル）−ｎ４［２−（プロパン−２−スルホニル）−フェニル］−ピリミジン−２，４−ジアミンの結晶形 - Google Patents

５−クロロ−ｎ２−（２−イソプロポキシ−５−メチル−４−ピペリジン−４−イル−フェニル）−ｎ４［２−（プロパン−２−スルホニル）−フェニル］−ピリミジン−２，４−ジアミンの結晶形 Download PDF

Info

Publication number
JP5916752B2
JP5916752B2 JP2013544762A JP2013544762A JP5916752B2 JP 5916752 B2 JP5916752 B2 JP 5916752B2 JP 2013544762 A JP2013544762 A JP 2013544762A JP 2013544762 A JP2013544762 A JP 2013544762A JP 5916752 B2 JP5916752 B2 JP 5916752B2
Authority
JP
Japan
Prior art keywords
phenyl
crystalline form
isopropoxy
chloro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013544762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545812A5 (enExample
JP2013545812A (ja
Inventor
フェング，リリー
ゴング，バオキング
エイチ． カルピンスキー，ピョートル
エイチ． カルピンスキー，ピョートル
マーリダール ウェイコーレ，リラダール
マーリダール ウェイコーレ，リラダール
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5916752(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013545812A publication Critical patent/JP2013545812A/ja
Publication of JP2013545812A5 publication Critical patent/JP2013545812A5/ja
Application granted granted Critical
Publication of JP5916752B2 publication Critical patent/JP5916752B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hydrogenated Pyridines (AREA)
JP2013544762A 2010-12-17 2011-12-15 ５−クロロ−ｎ２−（２−イソプロポキシ−５−メチル−４−ピペリジン−４−イル−フェニル）−ｎ４［２−（プロパン−２−スルホニル）−フェニル］−ピリミジン−２，４−ジアミンの結晶形 Active JP5916752B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061424194P 2010-12-17 2010-12-17
US61/424,194 2010-12-17
PCT/US2011/065030 WO2012082972A1 (en) 2010-12-17 2011-12-15 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Publications (3)

Publication Number Publication Date
JP2013545812A JP2013545812A (ja) 2013-12-26
JP2013545812A5 JP2013545812A5 (enExample) 2015-01-15
JP5916752B2 true JP5916752B2 (ja) 2016-05-11

Family

ID=45464892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013544762A Active JP5916752B2 (ja) 2010-12-17 2011-12-15 ５−クロロ−ｎ２−（２−イソプロポキシ−５−メチル−４−ピペリジン−４−イル−フェニル）−ｎ４［２−（プロパン−２−スルホニル）−フェニル］−ピリミジン−２，４−ジアミンの結晶形

Country Status (36)

Country Link
US (2) US9309229B2 (enExample)
EP (3) EP3121171B1 (enExample)
JP (1) JP5916752B2 (enExample)
KR (4) KR20130130022A (enExample)
CN (7) CN107056751A (enExample)
AR (2) AR084309A1 (enExample)
AU (1) AU2011343775B2 (enExample)
BR (1) BR112013015000A2 (enExample)
CA (1) CA2821102C (enExample)
CL (1) CL2013001723A1 (enExample)
CO (1) CO6801792A2 (enExample)
CY (2) CY1119474T1 (enExample)
DK (2) DK2651918T3 (enExample)
EC (1) ECSP13012770A (enExample)
ES (3) ES2643016T3 (enExample)
GT (1) GT201300153A (enExample)
HR (2) HRP20171477T1 (enExample)
HU (1) HUE041845T2 (enExample)
IL (1) IL226474A (enExample)
LT (2) LT2651918T (enExample)
MA (1) MA34771B1 (enExample)
MX (1) MX338210B (enExample)
MY (2) MY177742A (enExample)
NZ (1) NZ610713A (enExample)
PE (1) PE20140698A1 (enExample)
PH (1) PH12013501254A1 (enExample)
PL (2) PL2651918T3 (enExample)
PT (2) PT2651918T (enExample)
RS (1) RS57771B1 (enExample)
RU (2) RU2599785C3 (enExample)
SG (2) SG10201510082XA (enExample)
SI (2) SI2651918T1 (enExample)
TN (1) TN2013000216A1 (enExample)
TW (2) TWI576344B (enExample)
WO (1) WO2012082972A1 (enExample)
ZA (1) ZA201303599B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2651918T3 (pl) 2010-12-17 2017-12-29 Novartis Ag Krystaliczne formy 5-chloro-N2-(2-izopropoksy-5-metylo-4-piperydyn-4-ylofenylo)-N4-[2-(propano-2-sulfonylo)-fenylo]-pirymidyno-2,4-diaminy
CN104854101B (zh) 2012-11-06 2018-05-01 上海复尚慧创医药研究有限公司 Alk激酶抑制剂
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
CN105294649B (zh) * 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN105294650A (zh) * 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
PT3209647T (pt) 2014-10-21 2020-09-10 Ariad Pharma Inc Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
CN105601614A (zh) * 2014-11-21 2016-05-25 奥浦顿（上海）医药科技有限公司 一种色瑞替尼晶型及其制备方法
WO2016082795A1 (zh) * 2014-11-28 2016-06-02 苏州晶云药物科技有限公司 色瑞替尼的晶型i及其制备方法
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016108123A2 (en) * 2014-12-17 2016-07-07 Dr. Reddy’S Laboratories Limited Pure amorphous and amorphous solid dispersion of ceritinib
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2016098042A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
WO2017016529A1 (en) 2015-07-28 2017-02-02 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) * 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
WO2017152858A1 (zh) * 2016-03-11 2017-09-14 苏州晶云药物科技有限公司 色瑞替尼的晶型及其制备方法
US10604505B2 (en) 2016-03-15 2020-03-31 Natco Pharma Limited Modified process for the preparation of Ceritinib and amorphous form of Ceritinib
JP2019196359A (ja) * 2019-06-17 2019-11-14 ノバルティス アーゲー ピリミジン誘導体およびそれらの中間体を調製する化学的方法
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
KR102807411B1 (ko) 2020-01-17 2025-05-15 산동 수안주 파마 코포레이션 리미티드 다환 역형성 림프종 키나아제 억제제의 결정형
BR112022017437A2 (pt) * 2020-03-30 2022-10-18 Jiangsu Yahong Meditech Co Ltd Forma de cristal do pró-fármaco de nitroxolina, composição farmacêutica contendo o mesmo, e método de preparação e aplicação do mesmo
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
ATE542801T1 (de) * 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EA019941B1 (ru) * 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
JP5208123B2 (ja) * 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
BRPI0815979A2 (pt) * 2007-08-28 2017-06-13 Irm Llc compostos e composições com inibidores de quinase, bem como uso dos mesmos
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
AU2009233964B2 (en) * 2008-04-07 2012-06-07 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2011523646A (ja) * 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
EP2440534A2 (en) * 2009-06-10 2012-04-18 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
PL2651918T3 (pl) 2010-12-17 2017-12-29 Novartis Ag Krystaliczne formy 5-chloro-N2-(2-izopropoksy-5-metylo-4-piperydyn-4-ylofenylo)-N4-[2-(propano-2-sulfonylo)-fenylo]-pirymidyno-2,4-diaminy
KR20140017520A (ko) 2010-12-17 2014-02-11 이 아이 듀폰 디 네모아 앤드 캄파니 살진균제 아조사이클릭 아미드
ES2653717T3 (es) 2010-12-17 2018-02-08 Reata Pharmaceuticals, Inc. Pirazolil- y pirimidinil-enonas tricíclicas como moduladores antioxidantes de la inflamación
CN105294650A (zh) 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
CN107107792B (zh) 2014-11-21 2020-05-19 Tk控股公司 气囊模块
CN105622577A (zh) 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
AU2015358462A1 (en) 2014-12-04 2017-07-27 Bristol-Myers Squibb Company Combination of anti-CS1 and anti-PD1 antibodies to treat cancer (myeloma)
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2017016529A1 (en) 2015-07-28 2017-02-02 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用

Also Published As

Publication number Publication date
ZA201303599B (en) 2014-02-26
KR20180032680A (ko) 2018-03-30
CN106008462A (zh) 2016-10-12
CN106831716A (zh) 2017-06-13
SI3121171T1 (sl) 2018-11-30
SG10201510082XA (en) 2016-01-28
TW201629021A (zh) 2016-08-16
CY1121017T1 (el) 2019-12-11
ES2905973T3 (es) 2022-04-12
HUE041845T2 (hu) 2019-05-28
TN2013000216A1 (en) 2014-11-10
AU2011343775A1 (en) 2013-07-18
CN103282359A (zh) 2013-09-04
EP3453708B1 (en) 2021-10-27
CY1119474T1 (el) 2018-04-04
DK3121171T3 (en) 2018-12-10
PE20140698A1 (es) 2014-06-11
CL2013001723A1 (es) 2013-12-27
CO6801792A2 (es) 2013-11-29
EP3121171A1 (en) 2017-01-25
RS57771B1 (sr) 2018-12-31
EP3121171B1 (en) 2018-08-15
RU2016136823A3 (enExample) 2020-02-06
MY164810A (en) 2018-01-30
RU2013132947A (ru) 2015-01-27
NZ610713A (en) 2014-10-31
SG190856A1 (en) 2013-07-31
PT2651918T (pt) 2017-10-17
CN104262324A (zh) 2015-01-07
WO2012082972A1 (en) 2012-06-21
MX338210B (es) 2016-04-07
KR102325775B1 (ko) 2021-11-12
CN114989139A (zh) 2022-09-02
IL226474A (en) 2016-03-31
CN107056751A (zh) 2017-08-18
RU2746159C2 (ru) 2021-04-08
EP3453708A1 (en) 2019-03-13
CN112125884A (zh) 2020-12-25
KR20190022903A (ko) 2019-03-06
ES2696526T3 (es) 2019-01-16
TW201307299A (zh) 2013-02-16
MX2013006952A (es) 2013-07-15
RU2599785C2 (ru) 2016-10-20
KR20130130022A (ko) 2013-11-29
LT2651918T (lt) 2017-10-10
PL2651918T3 (pl) 2017-12-29
EP3453708B8 (en) 2022-03-16
DK2651918T3 (en) 2017-10-23
EP2651918A1 (en) 2013-10-23
HRP20181737T1 (hr) 2018-12-28
LT3121171T (lt) 2018-11-12
AU2011343775B2 (en) 2015-12-03
US20160175305A1 (en) 2016-06-23
PT3121171T (pt) 2018-11-27
CA2821102A1 (en) 2012-06-21
US9309229B2 (en) 2016-04-12
JP2013545812A (ja) 2013-12-26
GT201300153A (es) 2014-06-09
HRP20171477T1 (hr) 2017-11-17
SI2651918T1 (sl) 2017-10-30
IL226474A0 (en) 2013-07-31
MY177742A (en) 2020-09-23
ES2643016T3 (es) 2017-11-21
RU2599785C3 (ru) 2019-04-24
PH12013501254A1 (en) 2016-07-29
ECSP13012770A (es) 2013-10-31
AR084309A1 (es) 2013-05-08
BR112013015000A2 (pt) 2016-08-09
MA34771B1 (fr) 2013-12-03
TWI576343B (zh) 2017-04-01
CA2821102C (en) 2019-06-11
KR20200039021A (ko) 2020-04-14
RU2016136823A (ru) 2018-12-11
AR122395A2 (es) 2022-09-07
PL3121171T3 (pl) 2019-01-31
TWI576344B (zh) 2017-04-01
EP2651918B1 (en) 2017-07-12
US20130274279A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
US9309229B2 (en) Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
US9067896B2 (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof
US10005760B2 (en) Forms and compositions of an ERK inhibitor
CN102070618A (zh) 一种化合物及其晶体
HK40003121A (en) Process for the preparation of 5-chloro-n-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n-2-(isopropylsulfonyl)phenyl)-2,4-diamine di-hydrochloride
HK40003121B (en) Process for the preparation of 5-chloro-n-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n-2-(isopropylsulfonyl)phenyl)-2,4-diamine di-hydrochloride
HK1230180A1 (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
HK1186726B (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
HK1186726A (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
HK1230180B (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160405

R150 Certificate of patent or registration of utility model

Ref document number: 5916752

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250